CMMB
Price
$2.64
Change
+$0.14 (+5.60%)
Updated
Sep 26 closing price
Capitalization
13.7M
39 days until earnings call
FATE
Price
$1.00
Change
+$0.03 (+3.09%)
Updated
Sep 26 closing price
Capitalization
115.33M
31 days until earnings call
Interact to see
Advertisement

CMMB vs FATE

Header iconCMMB vs FATE Comparison
Open Charts CMMB vs FATEBanner chart's image
Chemomab Therapeutics
Price$2.64
Change+$0.14 (+5.60%)
Volume$288.49K
Capitalization13.7M
Fate Therapeutics
Price$1.00
Change+$0.03 (+3.09%)
Volume$1.31M
Capitalization115.33M
CMMB vs FATE Comparison Chart in %
Loading...
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMMB vs. FATE commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMMB is a Buy and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (CMMB: $2.64 vs. FATE: $1.00)
Brand notoriety: CMMB and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMMB: 284% vs. FATE: 90%
Market capitalization -- CMMB: $13.7M vs. FATE: $115.33M
CMMB [@Biotechnology] is valued at $13.7M. FATE’s [@Biotechnology] market capitalization is $115.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMMB’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CMMB’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than CMMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMMB’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CMMB’s TA Score: 5 bullish, 2 bearish.
  • FATE’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, CMMB is a better buy in the short-term than FATE.

Price Growth

CMMB (@Biotechnology) experienced а -0.38% price change this week, while FATE (@Biotechnology) price change was +3.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CMMB is expected to report earnings on Nov 07, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($115M) has a higher market cap than CMMB($13.7M). FATE YTD gains are higher at: -39.394 vs. CMMB (-63.536). CMMB has higher annual earnings (EBITDA): -12.61M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. CMMB (9.37M). CMMB has less debt than FATE: CMMB (0) vs FATE (81.3M). FATE has higher revenues than CMMB: FATE (8.47M) vs CMMB (0).
CMMBFATECMMB / FATE
Capitalization13.7M115M12%
EBITDA-12.61M-161.6M8%
Gain YTD-63.536-39.394161%
P/E RatioN/AN/A-
Revenue08.47M-
Total Cash9.37M223M4%
Total Debt081.3M-
FUNDAMENTALS RATINGS
CMMB vs FATE: Fundamental Ratings
CMMB
FATE
OUTLOOK RATING
1..100
266
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as CMMB (18). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CMMB (100). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as CMMB (99). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's Price Growth Rating (64) in the Biotechnology industry is in the same range as CMMB (95). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CMMB (100). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMMBFATE
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 18 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKRIF16.170.31
+1.95%
Bank Ireland Group PLC
HLFDY3.86N/A
N/A
Halfords Group Plc
CGXEF0.11N/A
-0.56%
CGX Energy Inc.
TPICQ0.03N/A
-3.27%
TPI Composites, Inc.
HUGPF47.37-1.66
-3.39%
Hugo Boss AG

CMMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with HURA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then HURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMMB
1D Price
Change %
CMMB100%
+5.60%
HURA - CMMB
34%
Loosely correlated
+0.41%
FATE - CMMB
32%
Poorly correlated
+3.01%
RXRX - CMMB
32%
Poorly correlated
+1.94%
AURA - CMMB
31%
Poorly correlated
+4.76%
TSHA - CMMB
31%
Poorly correlated
+6.21%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+3.01%
RXRX - FATE
53%
Loosely correlated
+1.94%
CRBU - FATE
52%
Loosely correlated
+10.36%
ALLO - FATE
50%
Loosely correlated
+4.17%
MGNX - FATE
50%
Loosely correlated
+4.85%
IPSC - FATE
50%
Loosely correlated
+4.39%
More